Stock Market News
Broker tips: BATS, Pharma, Wincanton
16-08-2011 12:59
| Add To Google +1 | Tweet |
Nomura has raised its estimates for cigarette giant British American Tobacco, as a result of a strong first half performance and a positive second half pricing outlook.
"Estimate increases are driven by encouraging first half organic performance (even ex Japan) and a positive pricing outlook going into the second half supported by additional price increases in Russia and Brazil, premiumisation and increased volumes in Japan," analysts said.
A buy rating is maintained.
Matrix has highlighted the effect that the patent infringement case won by US pharmaceutical group Pfizer will have on its London-listed peers, GlaxoSmithKline, AstraZeneca and Shire.
"Yesterday, Pfizer announced it had prevailed in its patent infringement action against generics company Teva Pharmaceuticals to protect a method-of-use‟ patent for one of its blockbuster drugs, Viagra," Matrix notes.
"This is a positive precedent for other existing method of use patents as well as future method of use patents, providing an addition hurdle for generics, thereby justifying a re-rating in the pharmaceutical sector given the heavy reliance on such patents," Matrix said.
The broker thinks that this will be positive for pharma stocks GlaxoSmithKline (buy with target price of 1,418p), AstraZeneca (reduce with target price of 2,806p) and Shire (buy with target of 1,951p).
Singer Capital Markets has kept its buy rating on aviation services and newspaper distribution group John Menzies following the firm's interim results.
"This should be the first year that Aviation exceeds Distribution in terms of contribution as market growth and market share gains continue to boost revenue and profit. Distribution continues to be weak as expected, though the prospect of a News of the World replacement remains likely," said analyst Andy Murphy.
Singer said that its target price of 632p implies a forward earnings multiple of 8.9, below the long-term average of 10.5.
BC
"Estimate increases are driven by encouraging first half organic performance (even ex Japan) and a positive pricing outlook going into the second half supported by additional price increases in Russia and Brazil, premiumisation and increased volumes in Japan," analysts said.
A buy rating is maintained.
Matrix has highlighted the effect that the patent infringement case won by US pharmaceutical group Pfizer will have on its London-listed peers, GlaxoSmithKline, AstraZeneca and Shire.
"Yesterday, Pfizer announced it had prevailed in its patent infringement action against generics company Teva Pharmaceuticals to protect a method-of-use‟ patent for one of its blockbuster drugs, Viagra," Matrix notes.
"This is a positive precedent for other existing method of use patents as well as future method of use patents, providing an addition hurdle for generics, thereby justifying a re-rating in the pharmaceutical sector given the heavy reliance on such patents," Matrix said.
The broker thinks that this will be positive for pharma stocks GlaxoSmithKline (buy with target price of 1,418p), AstraZeneca (reduce with target price of 2,806p) and Shire (buy with target of 1,951p).
Singer Capital Markets has kept its buy rating on aviation services and newspaper distribution group John Menzies following the firm's interim results.
"This should be the first year that Aviation exceeds Distribution in terms of contribution as market growth and market share gains continue to boost revenue and profit. Distribution continues to be weak as expected, though the prospect of a News of the World replacement remains likely," said analyst Andy Murphy.
Singer said that its target price of 632p implies a forward earnings multiple of 8.9, below the long-term average of 10.5.
BC
| Related share prices |
|---|
| AstraZeneca (AZN) share price |
| British American Tobacco (BATS) share price |
| GlaxoSmithKline (GSK) share price |
| Shire Plc (SHP) share price |
| Menzies(John) (MNZS) share price |
Stock News is provided by Digital Look Corporate Solutions from Sharecast news. Please read the terms and conditions of useage of this data. Republication or redistribution of content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd.
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- UK 100 Shares
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways share price
- Centrica share price
- Tesco share price
- National Grid share price
- RBS share price
- GSK share price
- Marks and Spencer
- Rolls Royce share price
- Banco Santander price
- Rio Tinto share price
- Amec Share price
- Corac share price
- Lookers share price
- Telecom plus share price
- Kier share price
- Punch taverns price
- Blinkx share price
- Tan share price
- Yell share price
- Rsa share price
- Pendragon share price
- Logica share price
- Bat share price
- Sky share price
- Kingfisher share price
- Dragon Oil share price
- Desire Petroleum share price
- RRL share price
- BPC share price
- VOG share price
- SAR share price


Prices

